COMMUNIQUÉS West-GlobeNewswire

Adaptive Biotechnologies Highlights New Data at 2025 ASCO Annual Meeting and EHA 2025 Congress Demonstrating How clonoSEQ® MRD Assessment is Optimizing Patient Care and Drug Development in Lymphoid Cancers
30/05/2025
30 scientific abstracts will be presented using clonoSEQ for MRD assessment across multiple types of blood cancers SEATTLE, May 30, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a [...]
Appili Therapeutics Announces Formal Termination of Arrangement Agreement with Aditxt Inc.
30/05/2025
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES HALIFAX, Nova Scotia, May 30, 2025 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “ [...]
BioCryst Highlights Real-world Data Showing ORLADEYO® (berotralstat) Consistently Reduces HAE Attacks Across All Ages
30/05/2025
New data shared at the 14th C1-inhibitor Deficiency & Angioedema Workshop supports berotralstat use at all stages of life RESEARCH TRIANGLE PARK, N.C., May 30, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc [...]
Conavi Medical Reports Fiscal Q2 2025 Interim Results and Operational Highlights
30/05/2025
New U.S. intracoronary imaging guidelines from the American College of Cardiology and recent peer-reviewed research strongly validate Novasight’s unique value proposition Upsized $20 million financing led by U.S. [...]
Amicus Therapeutics to Present at Upcoming Investor Conferences in June 2025
30/05/2025
PRINCETON, N.J., May 30, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming presentations at the following investor conferences in June. Jefferies [...]
Arvinas to Present at Jefferies Global Healthcare Conference
30/05/2025
NEW HAVEN, Conn., May 30, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company working to develop a new class of drugs based on targeted protein degradation, today announced that [...]
Cartesian Therapeutics Announces First Participant Enrolled in the Phase 3 AURORA Trial of Descartes-08 in Patients with Myasthenia Gravis
30/05/2025
FREDERICK, Md., May 30, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (“Cartesian” or the “Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today [...]
Ascend Aesthetic Partners Welcomes David Cutter as COO
30/05/2025
ATLANTA, May 30, 2025 (GLOBE NEWSWIRE) -- Ascend Aesthetic Partners (Ascend) is pleased to announce the addition of David Cutter as Chief Operating Officer. Cutter is a passionate leader who reflects our values of [...]
Instil Bio to Participate in the 2025 Jefferies Global Healthcare Conference
30/05/2025
DALLAS, May 30, 2025 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (Nasdaq: TIL, "Instil"), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies, today announced that Bronson Crouch, [...]
Standard BioTools to Host Inaugural “Proteomics Roundtable” Webcast Series
30/05/2025
Featuring top researchers and industry experts using high-throughput proteomics to drive breakthroughs in population health, translational research and clinical development SOUTH SAN FRANCISCO, Calif., May 30, 2025 ( [...]
Zymeworks Announces NMPA Approval of Zanidatamab in China for Adults with Previously Treated, Unresectable or Metastatic HER2-high expression (IHC3+) Biliary Tract Cancer
30/05/2025
Zanidatamab is the first and only dual HER2-targeted bispecific antibody approved for HER2+ biliary tract cancer in China; conditional approval based on the results of the HERIZON-BTC-01 clinical study $20 million [...]
Immuron Letter to Shareholders: Projects Update
30/05/2025
Highlights: Immuron on track to exceed A$7 million in Sales this financial year Uniformed Services University anticipates topline results of Travelan ® clinical study in October 2025 Immuron anticipates IMM-529 ( [...]
Le Québec a les cartes en main pour réduire les impacts des écrans sur la santé des jeunes
30/05/2025
MONTRÉAL, 30 mai 2025 (GLOBE NEWSWIRE) -- Après plusieurs mois de travaux et de consultations, la Commission spéciale sur les impacts des écrans et des réseaux sociaux sur la santé et le développement des jeunes (CSESJ [...]
Enterome presents positive Phase 1/2 MSS/pMMR metastatic colorectal cancer data in patients treated with EO4010 OncoMimics™ immunotherapy plus nivolumab at ASCO 2025
30/05/2025
Survival in 20 patients with MSS/pMMR mCRC at a median follow-up of 15.4 months was 40% at 12 months; median survival is currently 11.3 months Survival has currently reached plateau, with 34% (7/20) of patients still [...]
EssilorLuxottica to acquire Optegra clinics, another leap forward in its med-tech strategy
30/05/2025
EssilorLuxottica to acquire Optegra clinics, another leap forward in its med-tech strategy Acquisition of leading ophthalmology platform from MidEuropa will advance the Group’s development of the most comprehensive and [...]
EssilorLuxottica va acquérir les cliniques Optegra, une nouvelle étape clé dans sa stratégie med-tech
30/05/2025
EssilorLuxottica va acquérir les cliniques Optegra, une nouvelle étape clé dans sa stratégie med-tech Avec l’acquisition de cette plateforme d'ophtalmologie de premier plan auprès de MidEuropa, le Groupe vise à [...]
Itepekimab Met Primary Endpoint in One of Two Chronic Obstructive Pulmonary Disease (COPD) Phase 3 Trials
30/05/2025
AERIFY-1 trial met the primary endpoint of a statistically significant reduction in moderate or severe exacerbations in former smokers regardless of eosinophilic phenotype and provided a clinically meaningful benefit [...]
Roche’s fenebrutinib maintains near-complete suppression of disease activity and disability progression for up to two years in people with relapsing multiple sclerosis
30/05/2025
Patients on fenebrutinib had low relapse rates with data showing no active brain lesions or disability progression after nearly two years of treatment Phase III studies for fenebrutinib in relapsing and primary [...]
Press Release: Itepekimab met the primary endpoint in one of two COPD phase 3 studies
30/05/2025
Itepekimab met the primary endpoint in one of two COPD phase 3 studies AERIFY-1 study met its primary endpoint of a statistically significant reduction in moderate or severe exacerbations in former smokers regardless of [...]

Pages